AWK:NYSEAmerican Water Works Company, Inc. Analysis
Data as of 2026-06-09 - not real-time
$122.49
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
American Water Works (AWK) is trading at $122.49, well below its 20‑day, 50‑day and 200‑day moving averages of $124.14, $129.24 and $132.88, signaling a bearish technical backdrop. The RSI sits at 42, indicating neutral momentum, while the MACD histogram is positive and the MACD signal is classified as bullish, suggesting a potential short‑term rebound toward the $127.98 resistance level. Volume is on the rise, and the stock currently finds support near $120.57, giving a modest cushion against further downside.
Fundamentally, AWK delivers solid top‑line growth (5.7% YoY) and robust profitability (gross margin 60.8%, operating margin 33.2%, net margin 21.2%). However, the balance sheet is strained with a debt‑to‑equity ratio of 142% and negative free cash flow of $1.9 B, raising concerns about liquidity. The dividend remains attractive at 2.92% with a 58.7% payout and management’s 7‑9% annual growth guidance, bolstered by a $185 M PFAS settlement that could offset remediation costs. Analysts project a mean target of $135.73, implying roughly 10% upside, but the DCF‑derived fair value of $41.86 flags a significant overvaluation relative to current pricing. Pending rate cases in key jurisdictions could lift earnings, aligning with the reaffirmed FY2026 EPS guidance of $6.02‑$6.12.
Fundamentally, AWK delivers solid top‑line growth (5.7% YoY) and robust profitability (gross margin 60.8%, operating margin 33.2%, net margin 21.2%). However, the balance sheet is strained with a debt‑to‑equity ratio of 142% and negative free cash flow of $1.9 B, raising concerns about liquidity. The dividend remains attractive at 2.92% with a 58.7% payout and management’s 7‑9% annual growth guidance, bolstered by a $185 M PFAS settlement that could offset remediation costs. Analysts project a mean target of $135.73, implying roughly 10% upside, but the DCF‑derived fair value of $41.86 flags a significant overvaluation relative to current pricing. Pending rate cases in key jurisdictions could lift earnings, aligning with the reaffirmed FY2026 EPS guidance of $6.02‑$6.12.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages indicating bearish bias
- Support level near $120.57 and increasing volume
- Attractive dividend yield but high leverage
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Reaffirmed EPS guidance and expected rate case upside
- Dividend growth commitment of 7‑9% per year
- Analyst price targets suggesting ~10% upside
Long Term
> 3 yearsNeutral
Model confidence: 8/10
Key Factors
- Stable regulated revenue stream and defensive utility sector
- Consistent dividend payout with growth potential
- Debt reduction pressure and negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth5.70%
Profit Margin21.17%
P/E Ratio21.7
ROE10.22%
ROA3.51%
Debt/Equity142.33
P/B Ratio2.2
Op. Cash Flow$2.0B
Free Cash Flow$-1896625024
Industry P/E22.1
Technical Analysis
TrendBearish
RSI42.2
Support$120.57
Resistance$127.98
MA 20$124.14
MA 50$129.24
MA 200$132.88
MACDBullish
VolumeIncreasing
Fear & Greed Index87.64
Valuation
Fair Value$41.86
Target Price$135.73
Upside/Downside10.81%
GradeOvervalued
TypeValue
Dividend Yield2.92%
Risk Assessment
Beta-0.43
Volatility17.92%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.